82P Stock Chart & Stats
€22.20
€0.00(0.00%)
At close: 4:00 PM EDT
€22.20
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€15.40 - €23.40
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€920.71M
Enterprise Value€1.13K
Total Cash (Recent Filing)€202.18M
Total Debt (Recent Filing)€411.18M
Price to Earnings (P/E)219.6
Beta0.34
Next Earnings
Aug 04, 2026EPS Estimate
0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.12
Shares Outstanding39,334,984
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-1.51
Price to Book (P/B)1.66
Price to Sales (P/S)1.59
P/FCF Ratio8.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€27.84Price Target Upside25.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)2.53
Revenue Forecast (FY)€675.14M
Bulls Say, Bears Say
Bulls Say
Balance-sheet ResilienceMaterial debt reduction and a stronger debt-to-equity profile increase financial flexibility. A healthier balance sheet lowers interest burden, supports continued share repurchases or targeted R&D/investment, and reduces refinancing risk over the next 2–6 months.
Consistent Cash GenerationSustained positive operating and free cash flow underpins internal funding for operations, pipeline spending and capital returns. Even with recent slower FCF growth, the ability to self-fund initiatives and deleverage is a durable strength versus peers reliant on external financing.
Payer Access ExpansionSeparate commercial reimbursement across outpatient venues materially broadens addressable settings for EXPAREL, reducing a key adoption barrier. Durable payer recognition supports sustained procedure-level uptake and revenue diversification outside the surgical bundle over coming months.
Bears Say
Profitability VolatilityErratic profitability and currently thin operating and net margins constrain the company's ability to consistently generate returns. Low ROE and profit swings increase execution risk for funding growth and make earnings power fragile over the next 2–6 months.
Softening FCF MomentumAlthough FCF remains positive, the recent downshift in FCF growth reduces the cushion for incremental R&D, M&A or buybacks. A weakening FCF trajectory can limit strategic optionality and heighten sensitivity to operational disruptions in the medium term.
Payer Policy UncertaintyReimbursement gains hinge in part on NOPAIN policy constructs that currently have a sunset date. If policy changes or lapses, access and pricing dynamics for EXPAREL could be materially affected, posing a structural reimbursement risk over the next several quarters.
Pacira Pharmaceuticals News
82P FAQ
What was Pacira Pharmaceuticals’s price range in the past 12 months?
Pacira Pharmaceuticals lowest stock price was €15.40 and its highest was €23.40 in the past 12 months.
What is Pacira Pharmaceuticals’s market cap?
Pacira Pharmaceuticals’s market cap is €920.71M.
When is Pacira Pharmaceuticals’s upcoming earnings report date?
Pacira Pharmaceuticals’s upcoming earnings report date is Aug 04, 2026 which is in 4 days.
How were Pacira Pharmaceuticals’s earnings last quarter?
Pacira Pharmaceuticals released its earnings results on Apr 30, 2026. The company reported €0.524 earnings per share for the quarter, beating the consensus estimate of €0.478 by €0.045.
Is Pacira Pharmaceuticals overvalued?
According to Wall Street analysts Pacira Pharmaceuticals’s price is currently Undervalued.
Does Pacira Pharmaceuticals pay dividends?
Pacira Pharmaceuticals does not currently pay dividends.
What is Pacira Pharmaceuticals’s EPS estimate?
Pacira Pharmaceuticals’s EPS estimate is 0.56.
How many shares outstanding does Pacira Pharmaceuticals have?
Pacira Pharmaceuticals has 39,334,984 shares outstanding.
What happened to Pacira Pharmaceuticals’s price movement after its last earnings report?
Pacira Pharmaceuticals reported an EPS of €0.524 in its last earnings report, beating expectations of €0.478. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Pacira Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:82P
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pacira Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€27.84 (25.39% Upside)
€27.84 (25.39% Upside)
Blogger Sentiment
Bullish
DE:82P Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.60%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-23.83%
Trailing 12-Months
Company Description
Pacira Pharmaceuticals
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
82P Company Deck
82P Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominately positive picture: the company reported solid top-line momentum across core products (EXPAREL, ZILRETTA, ioverao) with meaningful YoY growth, strengthened IP protection, expanded reimbursement coverage (110M+ covered lives), encouraging pipeline progress with near-term readouts, and healthy adjusted EBITDA and buyback activity. Near-term challenges include revenue mix impacts from a new GPO and winter storms, modest margin compression and elevated SG&A/R&D spending tied to strategic initiatives, and policy timing risk around NOPAIN’s scheduled 2027 expiration. On balance the positives — sustainable product growth, strengthened commercial and IP positions, active pipeline catalysts, and disciplined capital returns — outweigh the lowlights.View all DE:82P earnings summaries82P Stock 12 Month Forecast
Average Price Target
€27.84
▲(25.39% Upside)
Technical Analysis
Teva Pharmaceutical
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―
Amneal Pharmaceuticals
―